Form 4: Cytek Biosciences Executive Yan Ming Reports Stock Transactions

Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On March 11, 2024, Yan Ming, the Chief Technology Officer of Cytek Biosciences, had 9,817 restricted stock units (RSUs) vest.
• Following the vesting, 2,911 shares were withheld by Cytek Biosciences to cover tax obligations at a price of $7.22 per share.
• After these transactions, Yan Ming directly owns 6,050,402 shares of Cytek Biosciences common stock and 88,362 restricted stock units.
• The RSUs vest over four years, with portions vesting on various dates in May, August, November, and March.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, and does not inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Executive compensation packages including RSUs are standard practice in the biotechnology industry to align management interests with shareholder value.
• Tax withholding practices related to RSU vesting are consistent across publicly traded companies.
• Comparable companies such as Bio-Rad Laboratories and Agilent Technologies also utilize RSU grants as part of their executive compensation plans.

Stakeholder Impact

• The transaction has a minor impact on shareholders due to the change in Yan Ming's holdings.
• The tax withholding impacts Yan Ming's personal finances.

Key Dates